Hot Pursuit     06-Jun-24
Indoco Remedies gains after receiving USFDA nod for type 2 diabetes drug
Indoco Remedies added 2.68% to Rs 317.55 after the company has received tentative approval from the US Food and Drug administration (USFDA) for its abbreviated new drug application (ANDA) for canagliflozin and metformin tablets.
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus. The product will be manufactured by the company at its manufacturing facility located at Goa. Canagliflozin and

Aditi Panandikar, managing director said, “We are excited to receive the tentative approval from the USFDA for our Canagliflozin and Metformin Hydrochloride Tablets. This milestone underscores our commitment to bringing affordable and effective treatment options to patients managing type 2 diabetes.”

Indoco is a fully integrated, research-oriented pharmaceutical company. The company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by an R&D Centre and a CRO facility.

Indoco Remedies consolidated revenue grew by 2.4% YoY to Rs 439.08 crore while the profit after tax declined by 14.6% YoY to Rs 22.03 crore.

Previous News
  Indoco Remedies consolidated net profit declines 14.70% in the December 2022 quarter
 ( Results - Announcements 24-Jan-23   12:32 )
  Indoco Remedies fixes record date for final dividend
 ( Market Beat - Reports 01-Sep-23   11:05 )
  Indoco Remedies declines after US FDA classifies Goa plant inspection as OAI
 ( Hot Pursuit - 05-Jun-23   09:20 )
  Indoco Remedies consolidated net profit rises 132.75% in the June 2021 quarter
 ( Results - Announcements 11-Aug-21   13:07 )
  Indoco Remedies schedules board meeting
 ( Corporate News - 13-May-23   14:57 )
  Indoco Remedies receives Establishment Inspection Report for its unit in Goa
 ( Corporate News - 03-May-23   16:23 )
  Indoco Remedies slumps after dismal Q3 performance
 ( Hot Pursuit - 24-Jan-23   12:37 )
  Indoco Remedies Ltd leads losers in 'B' group
 ( Hot Pursuit - 24-Jan-23   14:45 )
  Indoco Remedies' AnaCipher CRO successfully clears USFDA audit
 ( Corporate News - 19-Sep-22   11:22 )
  Indoco Remedies soars after its CRO clears US FDA inspection with zero 483s
 ( Hot Pursuit - 19-Sep-22   11:39 )
  Indoco Remedies standalone net profit rises 129.89% in the June 2021 quarter
 ( Results - Announcements 11-Aug-21   12:44 )
Other Stories
  Shalby drops after PAT slides 20% YoY to Rs 16 cr in Q1 FY25
  08-Jul-24   16:01
  Tata Steel Production rises 5% YoY in Q1 FY24
  08-Jul-24   15:54
  PC Jeweller soars after PNB approves settlement
  08-Jul-24   15:26
  Godrej Inds gains after chemicals arm inks BTA to acquire Ethoxylation Unit II
  08-Jul-24   15:22
  GE Power sizzles after NTPC order win
  08-Jul-24   15:02
  Patel Engineering Ltd leads losers in 'A' group
  08-Jul-24   15:01
  Sundaram Multi Pap Ltd leads losers in 'B' group
  08-Jul-24   14:46
  Marine Electricals jumps after order win
  08-Jul-24   14:33
  Volumes soar at Metro Brands Ltd counter
  08-Jul-24   14:30
  Bank of India Q1 domestic deposits grow 10% YoY
  08-Jul-24   14:25
Back Top